Sign In
Buy MEDIF
Medipharm Labs Earnings Calls
| Release date | May 12, 2026 |
| EPS estimate | -$0.0024 |
| EPS actual | -$0.0014 |
| EPS Surprise | 41.39% |
| Revenue estimate | 6.252M |
| Revenue actual | 6.444M |
| Revenue Surprise | 3.06% |
| Release date | Mar 30, 2026 |
| EPS estimate | -$0.0017 |
| EPS actual | -$0.0034 |
| EPS Surprise | -100.60% |
| Revenue estimate | 8.61M |
| Revenue actual | 10.238M |
| Revenue Surprise | 18.92% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.0022 |
| EPS actual | -$0.0037 |
| EPS Surprise | -69.77% |
| Revenue estimate | 8.913M |
| Revenue actual | 8.208M |
| Revenue Surprise | -7.91% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.0011 |
| EPS actual | -$0.0067 |
| EPS Surprise | -505.45% |
| Revenue estimate | 8.084M |
| Revenue actual | 8.667M |
| Revenue Surprise | 7.21% |
Last 4 Quarters for Medipharm Labs
Below you can see how MEDIF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $0.0568 |
| EPS estimate | -$0.0011 |
| EPS actual | -$0.0067 |
| EPS surprise | -505.45% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $0.0506 |
| Aug 11, 2025 | $0.0527 |
| Aug 12, 2025 | $0.0505 |
| Aug 13, 2025 | $0.0630 |
| Aug 14, 2025 | $0.0568 |
| Aug 15, 2025 | $0.0554 |
| Aug 18, 2025 | $0.0566 |
| Aug 19, 2025 | $0.0539 |
| Aug 20, 2025 | $0.0540 |
| 4 days before | 12.25% |
| 4 days after | -4.93% |
| On release day | -2.46% |
| Change in period | 6.72% |
| Release date | Nov 13, 2025 |
| Price on release | $0.0491 |
| EPS estimate | -$0.0022 |
| EPS actual | -$0.0037 |
| EPS surprise | -69.77% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $0.0522 |
| Nov 10, 2025 | $0.0515 |
| Nov 11, 2025 | $0.0515 |
| Nov 12, 2025 | $0.0521 |
| Nov 13, 2025 | $0.0491 |
| Nov 14, 2025 | $0.0530 |
| Nov 17, 2025 | $0.0512 |
| Nov 18, 2025 | $0.0500 |
| Nov 19, 2025 | $0.0475 |
| 4 days before | -5.94% |
| 4 days after | -3.26% |
| On release day | 7.94% |
| Change in period | -9.00% |
| Release date | Mar 30, 2026 |
| Price on release | $0.0470 |
| EPS estimate | -$0.0017 |
| EPS actual | -$0.0034 |
| EPS surprise | -100.60% |
| Date | Price |
|---|---|
| Mar 24, 2026 | $0.0483 |
| Mar 25, 2026 | $0.0492 |
| Mar 26, 2026 | $0.0480 |
| Mar 27, 2026 | $0.0495 |
| Mar 30, 2026 | $0.0470 |
| Mar 31, 2026 | $0.0460 |
| Apr 01, 2026 | $0.0485 |
| Apr 02, 2026 | $0.0478 |
| Apr 06, 2026 | $0.0453 |
| 4 days before | -2.75% |
| 4 days after | -3.72% |
| On release day | -2.13% |
| Change in period | -6.37% |
| Release date | May 12, 2026 |
| Price on release | $0.0620 |
| EPS estimate | -$0.0024 |
| EPS actual | -$0.0014 |
| EPS surprise | 41.39% |
| Date | Price |
|---|---|
| May 06, 2026 | $0.0666 |
| May 07, 2026 | $0.0622 |
| May 08, 2026 | $0.0662 |
| May 11, 2026 | $0.0635 |
| May 12, 2026 | $0.0620 |
| May 13, 2026 | $0.0635 |
| May 14, 2026 | $0.0650 |
| May 15, 2026 | $0.0628 |
| May 18, 2026 | $0.0639 |
| 4 days before | -6.91% |
| 4 days after | 3.06% |
| On release day | 2.35% |
| Change in period | -4.05% |
Medipharm Labs Earnings Call Transcript Summary of Q1 2026
MediPharm Labs reported Q1 2026 revenue of $9.0M (down from $10.8M YoY) driven by seasonality and international market adjustments, with international medical representing ~51% of revenue. Gross profit was $3.3M (37% margin), among the company's higher recent margins, reflecting branded international sales, disciplined mix and cost controls. Operating expenses declined 14% YoY and 28% sequentially, aided by restructuring actions expected to save ~$1M annually beginning in Q2. Adjusted EBITDA turned positive at $0.1M despite a net loss of $0.9M; the company exited the quarter with $9.9M cash, minimal debt and current tax/payable positions. Commercial progress included additional purchase orders and early shipments to France, expansion into New Zealand, continued growth in Germany (14% sequential), and an expected Brazil ramp in Q2. Strategy remains focused on regulated medical and pharma-grade opportunities, margin quality, selective M&A, and capital discipline—positioning MediPharm to benefit from evolving global regulatory shifts (including recent U.S. Schedule III rescheduling) while protecting patient service and margins amid domestic reimbursement pressure.
